clinical trial · NCT00781612
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
Genentech, Inc.·phase2·active not recruiting·n = 720
Neoplasm MetastasisDocetaxelPaclitaxelPertuzumabTrastuzumabTrastuzumab EmtansineAtezolizumab
brief summary
This is a global, multicenter, open-label safety extension study. Participants receiving single-agent trastuzumab emtansine or trastuzumab emtansine administered in combination with other anti-cancer therapies in a Genentech / Roche-sponsored parent study who are active and receiving benefit at the closure of parent study are eligible for continued treatment in this study.
started
Oct 16, 2008
primary completion
Sep 30, 2029
completion
Apr 30, 2030
last updated
Dec 24, 2025
official title
An Open-Label, Multicenter Extension Study of Trastuzumab Emtansine Administered as a Single Agent or in Combination With Other Anti-Cancer Therapies in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd-Sponsored Trastuzumab Emtansine Study
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol